

SECTOR: Specialty Pharmaceuticals

November 8, 2013

The USDA released its monthly WASDE (World Agriculture Supply and Demand Estimates) today. The report supports our belief that livestock expansion for poultry and swine will pick up in 2014 and cattle will pick up in 2015. This would be good for ZTS (BUY, \$31.04) because over 60% of its revenues come from livestock. The key data points that support our positive investment thesis are highlighted below.

- Corn (energy crop) production is forecast 146MM bushels higher at a record 13.989B bushels. Despite a late planted crop
 and July and August dryness across much of the Corn Belt, cooler-than-normal temperatures and an extended growing
 season have supported higher-than-expected yields for most producers. The projected season-average farm price for corn is
 lowered 30 cents at both ends of the range to \$4.10 to \$4.90 (down 29% to 41% YOY). Last year, the price of corn was \$6.90.
- Soybean (protein) production is projected at 3.258B bushels, up 109M, as higher yields more than offset lower harvested area. The U.S. season-average soybean price is projected at \$11.15 to \$13.15 per bushel (down 9% to 23% YOY), down \$0.35 at both ends of the range. Last year, the price of soybean was \$14.40.
- The forecasts for total red meat and poultry production for both 2013 and 2014 are lowered from September. For 2013, the
 beef production is nearly unchanged, as a lower third quarter estimate is largely offset by higher expected fourth quarter
 production. Pork production is reduced from last month based on third quarter data and a <u>lower-than-expected pace of</u>
 slaughter in October and early November.
- The broiler production forecast is lowered as higher third quarter production is more than offset by lower expected fourth quarter production. Turkey production is reduced for both the third and fourth quarters.
- For 2014, the beef production forecast is reduced slightly from September on <u>lower placements of cattle in feedlots during 2014.</u> We would note expectations for cattle recovery near term are modest, and the consensus view is that herd size will be down 1.0% to 1.5% when the cattle survey comes out in January 2014.
- The pork production forecast is reduced for 2014. In the September Hogs and Pigs report, <u>producers indicated intentions to expand sows farrowing through early 2014</u>, and increases in farrowings during 2014 will likely be supported by moderating <u>feed costs</u>. However, the 2014 pork production forecast has been tempered by continuing reports of porcine epidemic diarrhea (PED) outbreaks.
- Broiler production is raised as moderating feed costs support continued modest growth in broiler flocks. The turkey
 production forecast is reduced as turkey prices in the third quarter were weaker than expected and the contraction in
 production forecast for late 2013 is expected to carry into early 2014.

Potential Stock Moving Catalysts. 1) Operating margin expansion; 2) new product launches; 3) business development; 4) expansion into adjacent categories; 5) U.S. drought subsides



SECTOR: SPECIALTY PHARMACEUTICALS November 8, 2013

ANALYST CERTIFICATION

By issuing this research report, each Guggenheim Securities, LLC ("Guggenheim Securities") research analyst whose name appears in this report hereby certifies that (i) all of the views expressed in this report accurately reflect the research analyst's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst.

IMPORTANT DISCLOSURES


The research analyst(s) and research associate(s) have received compensation based upon various factors, including quality of research, investor client feedback, and Guggenheim Securities, LLC's overall revenues, which includes investment banking revenues.

Guggenheim Securities, LLC managed or co-managed a public offering of securities for Zoetis Inc. during the past 12 months.

Zoetis Inc. is or was during the 12-month period preceding the date of the distribution of this report a client of Guggenheim Securities. Guggenheim Securities, LLC Provided Zoetis Inc.investment banking services.

Guggenheim Securities, LLC or its affiliates expect(s) to receive or intend(s) to seek compensation for investment banking services from Zoetis Inc. in the next 3 months.

Please refer to this website for company-specific disclosures referenced in this report: https://guggenheimsecurities.bluematrix.com/sellside/Disclosures.action. Disclosure information is also available from Compliance, 330 Madison Avenue, New York, NY 10017.



RATING DEFINITIONS

BUY (B) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

NEUTRAL (N) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 15% within a 12-month period.

SELL (S) - Describes stocks that we expect to provide a total negative return (price appreciation plus yield) of 15% or more within a 12-month period.

NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Guggenheim Securities, LLC policies.

CS - Coverage Suspended. Guggenheim Securities, LLC has suspended coverage of this company.

NC - Not covered. Guggenheim Securities, LLC does not cover this company.

Restricted - Describes issuers where, in conjunction with Guggenheim Securities, LLC engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.

Monitor - Describes stocks whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.

Guggenheim Securities, LLC methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market



SECTOR: SPECIALTY PHARMACEUTICALS

November 8, 2013

risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

RATINGS DISTRIBUTIONS FOR GUGGENHEIM SECURITIES:

			IB Serv./ Past 12Mos.	
Rating Category	Count	Percent	Count	Percent
Buy	101	52.60%	13	12.87%
Neutral	90	46.88%	9	10.00%
Sell	1	0.52%	0	0.00%

OTHER DISCLOSURES

This research is for our clients and prospective clients only. Other than disclosures relating to Guggenheim Securities and its affiliates, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the research analyst's judgment. Guggenheim Securities conducts a full-service, integrated investment banking and brokerage business, and one or more of its affiliates conduct an investment management business. Guggenheim Securities is a member of SIPC (http://www.sipc.org). Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our employees trading for our own account that reflect opinions that are contrary to the opinions expressed in this research. Guggenheim Securities or certain of its affiliates conducts an investment management business, trades for its own account, and conducts an investment business, and may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research. We and our affiliates also may sell to or buy from customers on a principal basis the securities described herein. We and our affiliates also do business with, or that relates to, companies covered in Guggenheim Securities' research, and may have a position in the debt of the company or companies discussed herein.

This research is not an offer to sell or the solicitation of an offer to buy any security. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

TACTICAL TRADING IDEA DISCLAIMER

Guggenheim Securities, LLC produces "Tactical Trade Ideas" that identify short-term, catalyst-driven trading opportunities impacting companies within the Firm's coverage universe. Tactical Trade Ideas may exist on companies in this report and may be contrary to the analyst's published rating.

Copyright © 2013 by Guggenheim Securities, LLC, ("Guggenheim") a FINRA registered broker-dealer. All rights reserved. The contents of this report are based upon information or are obtained from sources that Guggenheim generally considers reliable, but Guggenheim makes no representations or warranties with respect to their accuracy, completeness, timeliness, suitability or otherwise, and assumes no responsibility to update them for subsequent events or knowledge. Guggenheim is not responsible for your use of this information.

Contact Information

NEW YORK SALES & TRADING DESK

212 292 4700

EQUITY TRADING DESK

212 292 4701

MEDIA INQUIRIES

310 367 6567

EMAIL

general@guggenheimcm.com

Locations

NEW YORK

ROSTON

330 Madison Avenue New York, NY 10017

WASHINGTON, DC

1055 Thomas Jefferson Street, NW Suite 450

500 Boylston Street, 13th Floor

Washington, DC 20007

Boston, MA 02116

DALLAS

Suite 4005

LOS ANGELES

1717 McKinney Avenue Suite 870 Dallas, TX 75202

Los Angeles, CA 90017

601 South Figueroa Street

SAN FRANCISCO 50 California Street San Francisco, CA 94111

NASHVILLE

104 Woodmont Blvd Suite 203 Nashville, TN 37205

HERNANDO

1288 Byhalia Road Suite 2

Hernando, MS 38632

Guggenheim Equity Research

AUTOMOTIVE

Matthew Stover, Analyst

matthew.stover@guggenheimpartners.com 617 859 4605

Brendon Mason, Associate

brendon.mason@guggenheimpartners.com 617 859 4624

ENERGY: EXPLORATION & PRODUCTION

Rob Cordray, Analyst

robert.cordray@guggenheimpartners.com 972 638 5509

Steven Hader, Associate

steven.hader@guggenheimpartners.com 972 638 5507

ENERGY: OIL SERVICES & EQUIPMENT Darren Gacicia. Analyst

darren.gacicia@guggenheimpartners.com 212 293 3054

Michael LaMotte, Analyst

michael.lamotte@guggenheimpartners.com 972 638 5502

Wilson Waggoner, Associate

wilson.waggoner@guggenheimpartners.com 972 638 5506

FINANCIAL SERVICES: LARGE-CAP BANKS

Marty Mosby, Analyst marty.mosby@guggenheimpartners.com

662 469 9595

Mason Mosby, Associate

mason.mosby@guggenheimpartners.com 662 469 9194

FINANCIAL SERVICES: REGIONAL & COMMUNITY BANKS, CARD NETWORKS

Taylor Brodarick, Analyst

taylor.brodarick@guggenheimpartners.com 615 208 1222

David Darst, Analyst

david.darst@guggenheimpartners.com 615 208 1224

Rahul Agarwal, Associate

rahul.agarwal@guggenheimpartners.com 615 208 1221

FINANCIAL SERVICES: INSURANCE Bijan Moazami, Analyst

bijan.moazami@guggenheimpartners.com 202 747 9466

HEALTHCARE: BIOTECH Bret Holley, Analyst

bret.holley@guggenheimpartners.com 212 293 2820

Daniel Chung, Associate

daniel.chung@guggenheimpartners.com 212 518 9771

HEALTHCARE: PHARMACEUTICALS

Louise Chen, Analyst

louise.chen@guggenheimpartners.com 212 381 4195

Swati Kumar, Associate

swati.kumar@guggenheimpartners.com 212 918 8754

RETAIL & CONSUMER John Heinbockel, Analyst

john.heinbockel@guggenheimpartners.com 212 381 4135

Steven Forbes, Associate

steven.forbes@guggenheimpartners.com 212 381 4188

TMT: CABLE & SATELLITE TV Sabina Nyckowski, Analyst

sabina.nyckowski@guggenheimpartners.com 212 292 4778

TMT: MEDIA & ENTERTAINMENT Michael Morris, Analyst

michael.morris@guggenheimpartners.com 646 357 6232

Curry Baker, Associate

curry.baker@guggenheimpartners.com 646 357 6684